Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Myrexis Inc.

Criteria

Inclusion Criteria:

• Refractory Brain Metastases

• At least 1 measurable intracranial lesion as defined by RECIST

• ECOG less than or equal to 1

• Adequate hematology/organ function

• No baseline peripheral or central neuropathy above grade 1

Exclusion Criteria:

• Hypersensitivity to Cremophor EL

• Pregnant or Lactating

• Spinal Cord Compression

• Pre-existing dementia/cognitive disfunction

• Require Neupogen or Neulasta to Maintain Neutrophil Count

• Have Primary Brain Cancer

• Have History of Ischemic Heart Disease

• Have Diabetes